MATV60 recombinant adenovirus vector, application, preparation method and HPV16 / 18 therapeutic vaccine

Abstract

The invention relates to the technical field of HPV therapeutic vaccines, in particular to an MATV60 recombinant adenovirus vector, application, a preparation method and an HPV 16 / 18 therapeutic vaccine. The MATV60 recombinant adenovirus vector is constructed by adopting E1 and E3 combined deletion replication-deficient human type 5 adenovirus, and a nucleotide sequence which is shown as SEQ ID No.1 and is used for coding E6 and E7 fusion proteins of HPV16 and HPV18 is connected to the E1 deletion position. The recombinant adenovirus vector can be applied to preparation of HPV16 / 18 therapeutic vaccines. The HPV 16 / 18 therapeutic vaccine containing the recombinant adenovirus vector has a good immune effect on high-risk HPV 16 / 18, is strong in pertinence and high in safety, and has a good effect on HPV persistent infection and neoplasia in cervix uteri, anus and vulva.

Images